What are your top takeaways in Breast Cancer from ESMO 2024?

The most interesting and impactful paper was LBA18 – DESTINY-Breast12 showing significant responses in HER2+ brain metastases – including untreated brain metastases. The median PFS and survivals were truly impressive

Abstract 3400, testing patritumab (HER3-targeting antibody-drug conjugate) in a Pha...

In the early BC area, I thought 3 abstracts were of major importance.

1. KN522 overall survival advantage for neoadjuvant/adjuvant pembrolizumab together with NACT. This strengthens the argument that patients meeting the KN522 eligibility criteria should receive preoperative therapy with IO, and not go...

1. NATALEE Trial (ER-positive/HER2-negative breast cancer): The NATALEE phase 3 trial tested ribociclib in the adjuvant setting alongside an aromatase inhibitor for stage 2 and 3 ER-positive/HER2-negative breast cancer. After four years, there was a nearly 5% improvement in invasive disease-free survi...

1. KEYNOTE-522
2. DESTINY-Breast12
3. NATALEE